• TCM Information Laboratory of Guangdong Second Traditional Chinese Medicine Hospital(TCM Engineering Technology Academy of Guangdong), Guangzhou, Guangdong 510095, P. R. China;
Export PDF Favorites Scan Get Citation

Objective To assess the effect of Xuezhikang 1.2 g/d after 4 weeks' treatment on primary hyperlipidemia patients' lipid contents including total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) by literature analysis. Methods A literature research was carried out in CNKI, Wanfang and Weipu full-text database to collect articles published from January 1st, 1994 to August 30 th, 2014, concerning the self-controlled trials on the lipid regulating effects of Xuezhikang 1.2 g/d for 4 weeks in primary hyperlipidemia patients. Statistical analysis was performed with Review Manager 5.2. Results Fifty-five independent trials were included in this review. All of the independent studies showed no homogeneity (P<0.01, I2>70%), and had publication bias. The contents of TC, TG, and LDL-C after a 4-week treatment with 1.2 g/d Xuezhikang were significantly lower than those before treatment [WMD=1.14 mmol/L, 95%CI (1.02, 1.25) mmol/L, P<0.000 01; WMD=0.72 mmol/L, 95%CI (0.59, 0.85) mmol/L, P<0.000 01; WMD=0.87 mmol/L, 95%CI (0.74, 1.00) mmol/L, P<0.000 01] and the contents of HDL-C was significantly higher than that before treatment [WMD=-0.16 mmol/L, 95%CI (-0.26, -0.12) mmol/L, P<0.000 01]. Conclusion Xuezhikang can reduce the primary hyperlipidemia patients' TC, TG and LDL-C, and increase HDL-C after 4 weeks' treatment.

Citation: DUJian-ping, ZHAOZi-ming, XIANeng-neng, RENWei. Reassessment of Lipid Regulating Effect of Xuezhikang on Primary Hyperlipidemia Patients: A Systematic Review. West China Medical Journal, 2015, 30(2): 254-262. doi: 10.7507/1002-0179.20150080 Copy

  • Previous Article

    An Investigation of Cardiovascular Risk Factors in Pre-diabetes Patients in Rural Areas of Chengdu City
  • Next Article

    Effect and Safety of Xueshuantong Combined with Conventional Western Medicine for Angina Pectoris in Coronary Heart Disease Patients: A Systematic Review